PTGX — Protagonist Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.84bn
- $8.05bn
- $46.02m
US FDA approves Takeda, Protagonist's drug for rare blood cancer (updated)
US FDA approves Takeda, Protagonist's drug for rare blood cancer
Silence Therapeutics jumps after mid-stage trial data for blood cancer drug
Protagonist Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Protagonist Therapeutics Q1 revenue doubles on ICOTYDE milestone
Brief: Protagonist Therapeutics Q1 EPS USD 0.05
US FDA approves J&J's oral psoriasis pill (updated)
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies
U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
Protagonist climbs after FDA approves oral psoriasis drug
US FDA approves J&J's oral psoriasis pill
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite
Protagonist Therapeutics Q4 revenue drops on lower milestone payments
Brief: Protagonist Therapeutics Q4 EPS USD -0.69
U.S. RESEARCH ROUNDUP- Agios Pharmaceuticals, Dycom Industries, Lowe's Companies
Protagonist Therapeutics Q3 net loss widens to $39.3 mln
Brief: Protagonist Therapeutics Q3 EPS USD -0.62
Street View: Protagonist's 'main character' energy draws J&J to potential takeover talks